San Diego–based Kura Oncology has landed U.S. Food and Drug Administration approval for Komzifti (ziftomenib), a once‑daily oral therapy for adults with relapsed or refractory acute myeloid leukemia that carry a susceptible NPM1 mutation. For local clinicians and patients who have seen standard treatments fail or the disease return, it is a fresh, targeted option in a space that does not get many of those.
FDA Sign-Off And The Company's Response
Kura and partner Kyowa Kirin announced the Nov. 13 approval in a company statement, and CEO Troy Wilson described the medicine as a meaningful advance for patients with limited options. In the announcement, Kura Oncology said it is ready to launch Komzifti and support patient access as the drug reaches the market.
How Komzifti Works And The Clinical Evidence
The decision is based on the KOMET‑001 trial, an open‑label study of 112 adults with relapsed or refractory NPM1‑mutant AML. In that trial, complete remission plus partial hematologic recovery (CR+CRh) was reported in about 21.4% of participants, and the median duration of those responses was roughly five months.
The FDA prescribing information sets the recommended dose at 600 mg once daily and highlights important safety considerations, including differentiation syndrome and QTc‑interval effects. According to the U.S. Food and Drug Administration, clinicians should monitor for these risks and manage them promptly if they occur.
Deal Terms And Who Runs The Launch
Kura entered into a global strategic collaboration with Kyowa Kirin in November 2024, which included a $330 million upfront payment and potential near-term milestone payments as part of a larger package of development and commercial milestones. Under the agreement, Kura will lead U.S. development and commercialization, while Kyowa Kirin oversees efforts outside the United States. Kura may receive tiered royalties on non‑U.S. sales. The financial structure and responsibilities are detailed in PR Newswire.
Local Impact And The Money Story
Headquartered in San Diego, Kura has been building out its commercial and clinical teams in advance of Komzifti's debut in real‑world practice. The company reported $727.4 million in cash, cash equivalents, and short‑term investments as of Dec. 31, 2024, in its filing with the U.S. Securities and Exchange Commission, and management says that cushion will help cover launch costs and late‑stage trials.
The San Diego Business Journal quoted Wilson estimating an initial addressable patient pool of "a couple thousand" and an early market opportunity in the low hundreds of millions of dollars annually if the drug is used in the relapsed setting.
Safety, Dosing And Access
Komzifti's label includes a boxed warning for differentiation syndrome and outlines monitoring and management steps for clinicians, in line with the FDA prescribing information. The recommended dose is 600 mg once daily, and Kura Oncology says it has created a support program, Kura RxKonnect, to help patients with access and reimbursement as the medicine rolls out.
Next Steps And Growing Competition
The partners are already pushing ahead with KOMET‑017, a pair of global Phase 3 frontline trials testing ziftomenib in combination regimens, and milestone payments tied to patient dosing have started to show up on Kura's balance sheet. The approval arrives in a crowded menin‑inhibitor race, including a recent green light for a rival drug, and early analysts and guideline groups are working out where Komzifti might settle in everyday practice, according to the Leukemia & Lymphoma Society.
For San Diego's life‑science scene, Komzifti's approval is another homegrown win in precision oncology and a new oral option for patients when standard approaches falter. Company leaders say they will begin the commercial rollout while continuing to push ahead with frontline trials and broader development plans.
